STAT Plus: Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said
At the conference, investors and doctor-specialists critiqued both approved and experimental drugs across nearly two dozen disease areas.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario